

Ref: FOI/GS/ID 8282

**Please reply to:**  
FOI Administrator  
Trust Management  
Maidstone Hospital  
Hermitage Lane  
Maidstone, Kent  
ME16 9QQ  
Email: [mtw-tr.foiadmin@nhs.net](mailto:mtw-tr.foiadmin@nhs.net)  
[www.mtw.nhs.uk](http://www.mtw.nhs.uk)

03 July 2023

## **Freedom of Information Act 2000**

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Breast Cancer.

*You asked:*

*Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:*

- a. Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)*
- b. Abemaciclib + Fulvestrant*
- c. Alpelisib + Fulvestrant*
- d. Anthracycline (e.g. doxorubicin or epirubicin) as a single agent*
- e. Atezolizumab + Nab-paclitaxel/Paclitaxel*
- f. Capecitabine as a single agent*
- g. Eribulin as a single agent or in combination*
- h. Everolimus + Exemestane*
- i. Fulvestrant as a single agent*
- j. Lapatinib*
- k. Neratinib*
- l. Parp Inhibitors (Olaparib/Talazoparib)*
- m. Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)*
- n. Palbociclib + Fulvestrant*
- o. Pembrolizumab*
- p. Platinum (e.g. carboplatin or cisplatin) as a single agent*
- q. Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)*
- r. Ribociclib + Fulvestrant*
- s. Sacituzumab Govitecan*
- t. Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent*
- u. Taxane and/or Anthracycline in combination*
- v. Trastuzumab as a single agent or in combination*
- w. Trastuzumab emtansine*

x. *Transtuzumab deruxtecan*

y. *Any other active systemic anti-cancer therapy*

Q2. *Does your trust participate in any clinical trials for the treatment of breast cancer? If so, please provide the name of each trial and the number of patients taking part.*

Trust response:

Q1.

a. 20

b. 2

c. 1

d. 0

e. 7

f. 32

g. 3

h. 9

i. 0

j. 0

k. 0

l. 0

m. 73

n. 25

o. 1

p. 1

q. 10

r. 1

s. 2

t. 29

u. 51

v. 90

w. 12

x. 3

y. 2

Q2.

These are trials are open to recruitment:

IRAS Number	Project Short title	Project site status	Recruited
1003524	heredERA	Open	0
273402	WO41554 A Study of GDC 0077 in patients with HR-Positive Breast Cancer	Open	0
95626	OPTIMA.	Open	46

These trials have closed to recruitment but are still in follow up, the number is the total patients recruited (not all may still be in follow up)

IRAS Number	Project Short title	Project site status	Recruited
1003435	persevERA Breast Cancer	Closed to recruitment - in follow up	2

126381	PAKT	Closed to recruitment - in follow up	3
127164	NCRN - 2372 - PD-0332991 + Letrozole in ER+ HER2- advanced BC	Closed to recruitment - in follow up	5
137785	POSNOC.	Closed to recruitment - in follow up	7
142447	UNIRAD	Closed to recruitment - in follow up	2